Research

In-Vitro

Results of numerous DNA fragmentation assays, employing normal, as well as cancerous cells including: LL/2, K562, U937, YAC-1, SP2/0, RAJI, B5T and CRL-1739 have affirmed, that while DNA of all the cancer cells can be destroyed within 10 minutes by CHML, no fragmentation of normal cellular DNA occurs.

These studies have established that CHML possesses an exciting and novel characteristic, which the company refers to as: "SELECTIVE CANCER CELL APOPTOSIS." Based upon many studies and extensive research, it appears that - unlike many anti-cancer drugs commonly used in chemotherapy - CHML primarily effects and destroys ABNORMAL cells.

In-Vivo

CHML has demonstrated the ability to cure a number of human mouse models, xenographically implanted with various forms of malignancy.

Human Clinical Studies

Glory has conducted clinical trials of its lead compound Cytotropic Heterogeneous Molecular Lipids (CHML), in human subjects diagnosed with a number of specific cancer conditions. Preliminary results have shown an unprecedented, durable response rate was attained. The most encouraging factor about these results is that CHML exhibited unparalleled efficacy, while there were virtually NO adverse reactions reported in any of the several hundred patients.*

Drug Licensing with the Food & Drug Administration (FDA)

Glory's objective is to be a leader in cancer therapy and to build an integrated pharmaceutical company focused on the oncology market.

To meet these objectives, the company intends to:
1. Pursue accelerated clinical development of Leverage the company's technology to fund clinical studies.
2. Commercialize products directly to focused physician groups.
3. Develop strategic collaborations for selected indications and markets.

The company's clinical trial strategy for its targeted indications is to identify subsets of larger patient populations in which clinical endpoints occur in high frequency and in a relatively short time frame. Glory plans to utilize data obtained in completed clinical trials for additional indications. The company believes that this strategy may allow it to reduce the size and duration of clinical trials, thereby generating statistically significant clinical results more quickly and cost effectively.

Cancer Indications - CHML has exhibited clinical efficacy against certain cancers, including liver, brain, colon and rectum, lung , breast, head and neck, stomach, skin, malignant lymphoma, leukemia , and metastasis cancers.

Experts estimate that in 2013 there were over 1.66 million individuals newly diagnosed with cancer in the United States. These included approximately 142,000 new cases of colon and rectum cancer, 30,000 new cases of liver & intrahepatic bile duct cancer, 23,000 new cases of brain & other nervous system tumor, 228,000 new cases of lung cancer, and 234,000 new cases of breast cancer.

An even more significant fact is - during this same year (2013) - over 580,000 American deaths were attributable to cancer. Glory maintains all intelectual property rights to CHML and its other compounds. The company plans to establish its own sales force, to first promote CHML for indications treated by a relatively small, well defined groups of clinical specialists. To reach larger physician groups, such as gynecologists, the company may enter into marketing agreements with pharmaceutical or biotechnology companies.

Glory also plans to seek partners for international development and commercialization of its products in all indications.

*Negative incidents were limited to several minor (grade 1) episodes. No grade 2, 3 or 4 toxicities were experienced by any participants.